" At the same time, we’re excited to be underway

" At the same time, we’re excited to be underway with our own Brilacidin oral formulation efforts to treat more extensive forms of IBD. We currently are utilizing sophisticated, controlled-release tablet technology to enable targeted delivery of oral Brilacidin in the colon, with in-human testing anticipated to start as soon as year-end. Millions of patients continue to suffer from hard-to-treat GI diseases, with recent deal-making in the pharmaceutical industry revealing significant premiums being paid for promising oral IBD drugs. As such, we are committed to advancing Brilacidin across multiple IBD indications, and also in other key franchise therapeutic areas, like our Phase 3-ready oral rinse Brilacidin program in Oral Mucositis.”

1)At the same time, we’re excited to be underway with our own Brilacidin oral formulation efforts to treat more extensive forms of IBD.

2) As such, we are committed to advancing Brilacidin across multiple IBD indications

3)and also in other key franchise therapeutic areas, like our Phase 3-ready oral rinse Brilacidin program in Oral Mucositis.”

Looks like this deal has "firmed up the ground" IPIX is standing on and moving forward as shown above. The idea of Leo not divulging the amount of the initial payment must have strategic reasons.
Could it be that IPIX is still negotiating with someone over B-OM and for some reason (smile) don't want the suitor to know the size of the initial payment??

Lots more news to come!!

Kelt